A core component of Bridgehead Consulting's activity is the technical and commercial evaluation of new ideas, products, technologies and development programmes.
Bridgehead Consulting' findings are widely used by clients for the purposes of planning and prioritisation, and to support investment decisions.
Bridgehead Consulting offers a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience, ensuring that projects are completed to the highest standards.
With an excellent track record with projects of this kind, Bridgehead Consulting work for a broad spectrum of companies and financial institutions.
Examples of recent projects include:
- Opportunity assessment
- Valuation
- Due diligence
- Expert reports
- Competitive assessment
- Qualitative market research
- Due diligence report on a company developing a novel synthetic antibody technology
- Valuation of intellectual property in the peptide therapeutics field, for tax purposes
- Due diligence on a company in the field of regenerative medicine
- Opportunity assessment and market evaluation for a novel wound healing technology
- Valuation to support forensic accountants in a licensing dispute
- Valuation of early stage pipeline prior to merger
- Technical and commercial due diligence on a novel high- throughput screening tool
- Review of anti-viral markets prior to project investment decisions
- Review of the technologies, development plans and costs and forecasts on behalf of investors
- Preparation of expert reports and other supporting documentation for public flotation: Alizyme plc UK, GeneMedix plc UK and Singapore, GW Pharmaceuticals Ltd UK, Akers Bioscience Ltd UK
Contact:
| Fiona Paton | Director, Technical and commercial evaluation |
With over 500 years combined experience in the healthcare industry, Bridgehead consultants can provide independent and objective analysis, backed up by sound commercial judgement, to advise and support senior management across a range of issues.
From early stage support with intellectual property strategy, business plans and fund raising, to commercialisation strategy, R&D portfolio management and top level corporate advice, our methods ensure ownership of the resulting plans by the principals who will ultimately be responsible for implementation.
- Corporate strategy
- Intellectual property strategy
- Portfolio management
- Business planning
- Fund raising support
In addition, Bridgehead Consulting is at the forefront in the development of financial evaluation and decision-analysis tools for the biopharmaceutical sector, which can prove invaluable for companies faced with hard portfolio selection decisions.
Bridgehead Consulting works under strict confidentiality and will not divulge the name of its clients or the nature of the work being carried out without express consent.
Examples of recent projects include:
- Review and development of corporate strategy for a UK pharmaceutical company
- Development of production strategy for a UK biotechnology company
- Development of valuation methodology to support portfolio management decisions for a European pharmaceutical company
- Review of IP strategy for an international biotechnology company
- Development of IP and patent protection strategy for a European biotechnology company
- Development of IP strategy for a European natural products company
- Development of business plans and independent fund raising documents for a variety of small to medium sized organisations
Contact:
| David Alcraft | Director |
We specialise in this area to provide input for all projects.
Telephone and face-to-face interviews are run with medical opinion formers, paramedical and nursing staff and patients.
Focus groups are run face to face and by telephone with the same target groups.
Our work has underpinned many major decisions in the industry and is highly regarded.
Contact:
| Fiona Paton | Director, Technical and commercial evaluation |
A core component of Bridgehead Consulting's activity is the technical and commercial evaluation of new ideas, products, technologies and development programmes.
Bridgehead Consulting' findings are widely used by clients for the purposes of planning and prioritisation, and to support investment decisions.
Bridgehead Consulting offers a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience, ensuring that projects are completed to the highest standards.
With an excellent track record with projects of this kind, Bridgehead Consulting work for a broad spectrum of companies and financial institutions.
Examples of recent projects include:
- Opportunity assessment
- Valuation
- Due diligence
- Expert reports
- Competitive assessment
- Qualitative market research
- Due diligence report on a company developing a novel synthetic antibody technology
- Valuation of intellectual property in the peptide therapeutics field, for tax purposes
- Due diligence on a company in the field of regenerative medicine
- Opportunity assessment and market evaluation for a novel wound healing technology
- Valuation to support forensic accountants in a licensing dispute
- Valuation of early stage pipeline prior to merger
- Technical and commercial due diligence on a novel high- throughput screening tool
- Review of anti-viral markets prior to project investment decisions
- Review of the technologies, development plans and costs and forecasts on behalf of investors
- Preparation of expert reports and other supporting documentation for public flotation: Alizyme plc UK, GeneMedix plc UK and Singapore, GW Pharmaceuticals Ltd UK, Akers Bioscience Ltd UK
Contact:
| Fiona Paton | Director, Technical and commercial evaluation |
Pricing, reimbursement and market access are key elements in the profitable commercialisation of new products. Companies need to start planning far earlier in their development process.
can draw on a wide range of skills and experience, including direct experience from both a company and a payer perspective, to advise companies in all stages of product development and commercialisation.
Our services range from initial market assessments focusing on pricing and reimbursement potential and risks, through the development of value messages to meet the concerns of payers and budget holders, to the formulation of pricing and reimbursement strategies and supporting clients through their implementation.
- Public policy assessment
- Pricing assessment
- Market access support
- Pricing strategy
- Reimbursement negotiation strategy
We use a variety of methodologies and techniques, including the creation of therapy and market specific funding and patient flow maps, reviews of the available information and arguments from a payer perspective, payer discussion programmes, qualitative and quantitative pricing studies, modelling of parallel trade risks and optimal launch sequences by market and the creation of both generic and market specific reimbursement support dossiers.
Examples of recent projects include:
- Pricing strategy for a novel bio-analytical instrumentation system
- Pricing strategy for an early stage oncology therapy
- Pricing survey of cancer therapies in Europe and the US - European Biotech company
- General advice on European pricing strategy and parallel trade issues for a US based company
- Pricing assessment and preliminary pricing strategy for an innovative NCE for a UK-based biotechnology company
- Overview of global pricing and reimbursement systems for a national industry association
- Advice on reimbursement dossier development and negotiation strategies in Europe for a key strategic product from a global pharmeceutical company
Contact:
| Jim Furness | Director, Pricing and reimbursement |
Our client is a licensed manufacturer of a range of aseptically processed sterile solutions administered by subcutaneous injection. The manufacturing unit specialises in the pilot scale production of parenterals.
The unit is capable of manufacturing small batches of injectable solution in vials for use in Phase 1 or early Phase 2 clinical studies to assess the characteristics of novel compounds in healthy volunteers.
The unit holds a current Manufacturing Licence for a range of sterile solutions administered by subcutaneous injection.
The manufacturing unit is available on a contract basis for the small scale manufacture of sterile solutions for parenteral administration.
Our client is seeking to provide contract manufacturing services to pharmaceutical, biotech and drug delivery companies who are looking to scale up products in development in readiness for phase 1-2 clinical studies.
Contact:
| Steve Poile | Director, Licensing and alliances |
| David Alcraft | Director |
Bridgehead International wins The Queen's Award for Enterprise (21 May 2007)
Bridgehead International has been honoured with The Queen's Award for Enterprise 2007, in the International Trade section, for outstanding achievement in international trade
A unique mix of scientific, technical, intellectual property and business consultants, Bridgehead Consulting has completed over 300 projects for clients in biotechnology, pharmaceutical, medical devices and diagnostic sectors.
Bridgehead Consulting consists of 50 staff and associates with over 500 years combined experience in the healthcare industry. The services supplied by these very experienced individuals can be divided into four categories:
- Technical and commercial evaluation - Bridgehead Consulting offers a powerful combination of strategic, scientific, medical, technical, commercial, economic, decision support, modelling and intellectual property skills and experience, ensuring that projects are completed to the highest standards
- Licensing and alliances - We provide a comprehensive, customised licensing service, including search and find, disposals, deal benchmarking, due diligence and valuation of in-licensing opportunities
- Pricing and reimbursement strategy - We can draw on a wide range of skills and experience, including direct experience from both a company and a payer perspective, to advise companies in all stages of product development and commercialisation
- Strategy and planning - From early stage support with intellectual property strategy, business plans and fund raising, to commercialisation strategy, R&D portfolio management and top level corporate advice, our methods ensure ownership of the resulting plans by the principals who will ultimately be responsible for implementation
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
